Fundraising FoxMission Biocapital — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Director & Chief Scientific Advisor)inCam Gallagher(President & Chief Executive Officer)inJohn Maroney(Executive Officer, Director)in
BoardZachary Collins(Executive Officer)inAnnie Mitsak(Director)in
Board seatDouglas CrawfordSteve Tregay· per SEC Form D
Co-investorsCure VenturesMission Bay Capital
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Board seatCassidy Blundell· per SEC Form D
Co-investorsAgent CapitalGimvLongwood FundNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture Investments+5 more
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Founder, Chief Executive Officer)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Board seatJohannes Fruehauf· per SEC Form D
Co-investorsALS Investment FundDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMitsui Global Investment+8 more
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesInkefMRL Ventures FundNextech InvestRA Capital
Zag Bio develops thymus-targeted bifunctional antibodies designed to induce central tolerance for treating autoimmune diseases.
BiotechDeep TechHealthtechMedical DevicesCambridge, US
Alan Crane(Founder)Diane Mathis(Founder)Joanne Lim(Co-founder)Dr. Diane Mathis(Founder)Jo Viney(Founder)John Kulman(Founder)
Co-investorsLightspeed Venture PartnersPear VCSanofi VenturesPolaris PartnersThe Engine Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.